

# Robert A Hauser

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5443797/publications.pdf>

Version: 2024-02-01

230  
papers

19,669  
citations

15504

65  
h-index

11939

134  
g-index

234  
all docs

234  
docs citations

234  
times ranked

12147  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lewy bodyâ€like pathology in long-term embryonic nigral transplants in Parkinson's disease. <i>Nature Medicine</i> , 2008, 14, 504-506.	30.7	1,472
2	The Parkinson Progression Marker Initiative (PPMI). <i>Progress in Neurobiology</i> , 2011, 95, 629-635.	5.7	1,278
3	Neuropathological Evidence of Graft Survival and Striatal Reinnervation after the Transplantation of Fetal Mesencephalic Tissue in a Patient with Parkinson's Disease. <i>New England Journal of Medicine</i> , 1995, 332, 1118-1124.	27.0	868
4	A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 1268-1278.	27.0	830
5	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REALâ€PET study. <i>Annals of Neurology</i> , 2003, 54, 93-101.	5.3	820
6	Highâ€frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. <i>Annals of Neurology</i> , 1997, 42, 292-299.	5.3	508
7	Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. <i>Annals of Neurology</i> , 1995, 38, 379-388.	5.3	421
8	Long-term Evaluation of Bilateral Fetal Nigral Transplantation in Parkinson Disease. <i>Archives of Neurology</i> , 1999, 56, 179.	4.5	347
9	KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. <i>American Journal of Psychiatry</i> , 2017, 174, 476-484.	7.2	339
10	Long-term evaluation of deep brain stimulation of the thalamus. <i>Journal of Neurosurgery</i> , 2006, 104, 506-512.	1.6	325
11	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 543.	9.0	312
12	Randomized controlled trial of deutetrabenazine for tardive dyskinesia. <i>Neurology</i> , 2017, 88, 2003-2010.	1.1	296
13	Randomized trial of the adenosine A <sub>2A</sub> receptor antagonist istradefylline in advanced PD. <i>Neurology</i> , 2003, 61, 297-303.	1.1	294
14	Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Psychiatry</i> , 2017, 4, 595-604.	7.4	291
15	Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. <i>Movement Disorders</i> , 1998, 13, 383-393.	3.9	271
16	Transplanted dopaminergic neurons develop PD pathologic changes: A second case report. <i>Movement Disorders</i> , 2008, 23, 2303-2306.	3.9	247
17	A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia. <i>Clinical Neuropharmacology</i> , 2000, 23, 75-81.	0.7	237
18	Manganese intoxication and chronic liver failure. <i>Annals of Neurology</i> , 1994, 36, 871-875.	5.3	235

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study. <i>Movement Disorders</i> , 2005, 20, 783-791.	3.9	234
20	Use of Placebo Surgery in Controlled Trials of a Cellular-Based Therapy for Parkinson's Disease. <i>New England Journal of Medicine</i> , 1999, 341, 988-992.	27.0	230
21	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007, 22, 2409-2417.	3.9	221
22	Identification of motor and nonmotor wearing-off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment. <i>Movement Disorders</i> , 2005, 20, 726-733.	3.9	219
23	Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. <i>Movement Disorders</i> , 2008, 23, 690-699.	3.9	219
24	Pramipexole-induced somnolence and episodes of daytime sleep. <i>Movement Disorders</i> , 2000, 15, 658-663.	3.9	209
25	Hypertensive Encephalopathy. <i>Archives of Neurology</i> , 1988, 45, 1078.	4.5	205
26	Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. <i>Movement Disorders</i> , 2008, 23, 2177-2185.	3.9	198
27	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. <i>Lancet Neurology</i> , The, 2011, 10, 415-423.	10.2	192
28	Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. <i>Lancet Neurology</i> , The, 2011, 10, 221-229.	10.2	188
29	Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. <i>Lancet Neurology</i> , The, 2013, 12, 346-356.	10.2	182
30	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 804-822.	46.4	178
31	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations. <i>JAMA Neurology</i> , 2017, 74, 216.	9.0	171
32	Parkinson's disease home diary: Further validation and implications for clinical trials. <i>Movement Disorders</i> , 2004, 19, 1409-1413.	3.9	169
33	Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study. <i>Movement Disorders</i> , 2004, 19, 426-432.	3.9	164
34	A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. <i>Movement Disorders</i> , 2008, 23, 2194-2201.	3.9	162
35	Levodopa: Past, Present, and Future. <i>European Neurology</i> , 2009, 62, 1-8.	1.4	158
36	Factors Associated With the Development of Motor Fluctuations and Dyskinesias in Parkinson Disease. <i>Archives of Neurology</i> , 2006, 63, 1756.	4.5	153

#	ARTICLE	IF	CITATIONS
37	Sertraline for the treatment of depression in parkinson's disease. <i>Movement Disorders</i> , 1997, 12, 756-759.	3.9	145
38	Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. <i>Lancet Neurology</i> , The, 2011, 10, 509-519.	10.2	145
39	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study). <i>JAMA Neurology</i> , 2017, 74, 941.	9.0	137
40	Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). <i>Movement Disorders</i> , 2017, 32, 1701-1709.	3.9	134
41	Determination of minimal clinically important change in early and advanced Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 813-818.	3.9	127
42	Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 564-573.	3.9	126
43	Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 979-983.	3.9	121
44	Droxidopa for the symptomatic neurogenic orthostatic hypotension in Parkinson's disease (n=306). <i>Movement Disorders</i> , 2015, 30, 646-654.	3.9	121
45	Sildenafil citrate (viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 305-308.	3.9	120
46	Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. <i>Lancet Neurology</i> , The, 2014, 13, 767-776.	10.2	120
47	Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 541-550.	3.9	112
48	Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. <i>Movement Disorders</i> , 2004, 19, 916-923.	3.9	111
49	Blood Manganese Correlates with Brain Magnetic Resonance Imaging Changes in Patients with Liver Disease. <i>Canadian Journal of Neurological Sciences</i> , 1996, 23, 95-98.	0.5	108
50	NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. <i>Movement Disorders</i> , 2015, 30, 1681-1687.	3.9	105
51	Wearing-off scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2011, 26, 2169-2175.	3.9	101
52	A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. <i>Movement Disorders</i> , 2007, 22, 279-282.	3.9	90
53	Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2010, 25, 1131-1142.	3.9	90
54	Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2246-2252.	3.9	90

#	ARTICLE	IF	CITATIONS
55	Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2542-2549.	3.9	87
56	Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). <i>Neurology</i> , 2012, 79, 163-169.	1.1	86
57	Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 858-866.	3.9	85
58	Head injury, alpha-synuclein Rep1, and Parkinson's disease. <i>Annals of Neurology</i> , 2012, 71, 40-48.	5.3	83
59	Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 145-154.	10.2	82
60	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Neurology</i> , The, 2020, 19, 135-144.	10.2	80
61	End-of-dose Wearing Off in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2006, 29, 312-321.	0.7	78
62	A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1356-1365.	3.9	78
63	The independent influence of apathy and depression on cognitive functioning in Parkinson's disease.. <i>Neuropsychology</i> , 2010, 24, 721-730.	1.3	76
64	Magnetic Resonance Imaging of Corticobasal Degeneration. <i>Journal of Neuroimaging</i> , 1996, 6, 222-226.	2.0	69
65	Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 1205-1209.	3.9	69
66	Efficacy, Tolerability, and Immunogenicity of OnabotulinumtoxinA in a Randomized, Double-Blind, Placebo-Controlled Trial for Cervical Dystonia. <i>Clinical Neuropharmacology</i> , 2012, 35, 208-214.	0.7	69
67	Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 961-968.	3.9	67
68	Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 115-116.	3.9	67
69	Levodopa-Induced Dyskinesias in Parkinson's Disease: Etiology, Impact on Quality of Life, and Treatments. <i>European Neurology</i> , 2008, 60, 57-66.	1.4	67
70	Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1366-1372.	3.9	67
71	A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. <i>Movement Disorders</i> , 2007, 22, 1660-1663.	3.9	63
72	Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. <i>Neurology</i> , 1998, 51, 912-913.	1.1	61

#	ARTICLE	IF	CITATIONS
73	Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 485-489.	3.9	60
74	The nosology of tardive syndromes. <i>Journal of the Neurological Sciences</i> , 2018, 389, 10-16.	0.6	60
75	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADYâ€PD III). <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 360-368.	3.7	59
76	Hyperactivity and hypoactivity in a rat model of Huntington's disease: the systemic 3-nitropropionic acid model. <i>Brain Research Protocols</i> , 1997, 1, 253-257.	1.6	58
77	Modafinil treatment of pramipexole-associated somnolence. <i>Movement Disorders</i> , 2000, 15, 1269-1271.	3.9	58
78	Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. <i>Neurology</i> , 2017, 88, 2198-2206.	1.1	58
79	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. <i>Neurology</i> , 2021, 97, 942-957.	1.1	58
80	Adenosine A2A Receptor Antagonists for Parkinson's Disease. <i>Drugs and Aging</i> , 2005, 22, 471-482.	2.7	55
81	&lt;p&gt;Impact of non-motor symptoms in Parkinson's disease: a PMDAAlliance survey&lt;/p&gt;. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2205-2212.	2.2	55
82	Levodopa/carbidopa/entacapone (Stalevo). <i>Neurology</i> , 2004, 62, S64-71.	1.1	55
83	Essential Tremor. <i>Neurologist</i> , 2004, 10, 250-258.	0.7	54
84	Future Treatments for Parkinson's Disease: Surfing the PD Pipeline. <i>International Journal of Neuroscience</i> , 2011, 121, 53-62.	1.6	51
85	Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release. <i>Parkinson's Disease</i> , 2014, 2014, 1-8.	1.1	51
86	Istradefylline â€“ a first generation adenosine A<sub>2A</sub> antagonist for the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 317-333.	2.8	51
87	Levodopa response in early Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2328-2336.	3.9	50
88	[ <sup>123</sup> I]FPâ€CIT (DaTscan) SPECT Brain Imaging in Patients with Suspected Parkinsonian Syndromes. <i>Journal of Neuroimaging</i> , 2012, 22, 225-230.	2.0	49
89	Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension. <i>Clinical Neuropharmacology</i> , 2016, 39, 220-226.	0.7	49
90	Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease. <i>Metabolic Brain Disease</i> , 1998, 13, 43-53.	2.9	48

#	ARTICLE	IF	CITATIONS
91	A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. <i>Movement Disorders</i> , 1998, 13, 643-647.	3.9	48
92	Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 359-365.	3.9	48
93	Long-term effects of rasagiline and the natural history of treated Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1489-1496.	3.9	45
94	Medical Management and Prevention of Motor Complications in Parkinson's Disease. <i>Neurotherapeutics</i> , 2020, 17, 1339-1365.	4.4	45
95	Duodenal levodopa infusion for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 657-664.	1.8	44
96	Levodopa-induced Dyskinesia in Parkinson's disease: Epidemiology, etiology, and treatment. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 302-310.	4.2	42
97	Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects. <i>Clinical Neuropharmacology</i> , 2010, 33, 5-10.	0.7	42
98	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. <i>Journal of Parkinson's Disease</i> , 2017, 7, 511-522.	2.8	42
99	Dyskinesia Matters. <i>Movement Disorders</i> , 2020, 35, 392-396.	3.9	42
100	Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with parkinson's disease. <i>Movement Disorders</i> , 1993, 8, 512-514.	3.9	41
101	Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials. <i>Movement Disorders</i> , 2011, 26, 1464-1476.	3.9	38
102	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS). <i>JAMA Neurology</i> , 2016, 73, 102.	9.0	38
103	Phenomenology and treatment of tremor disorders. <i>Neurologic Clinics</i> , 2001, 19, 651-680.	1.8	37
104	Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 175-180.	2.2	37
105	Efficacy, safety, and tolerability of overnight switching from immediate to once daily extended-release pramipexole in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2326-2332.	3.9	36
106	Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls. , 2020, 11, 679.		36
107	The Controversy Concerning Plasma Homocysteine in Parkinson Disease Patients Treated with Levodopa Alone or with Entacapone. <i>Clinical Neuropharmacology</i> , 2006, 29, 106-111.	0.7	35
108	Caffeine and Progression of Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2008, 31, 189-196.	0.7	35

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetics of ADS-5102 (Amantadine) Extended-Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. <i>Clinical Pharmacokinetics</i> , 2019, 58, 77-88.	3.5	35
110	Double-blind study of pramipexole, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 738-746.	3.9	32
111	Adult Chediak-Higashi Parkinsonian syndrome with dystonia. <i>Movement Disorders</i> , 2000, 15, 705-708.	3.9	31
112	Patient Evaluation of a Home Diary to Assess Duration and Severity of Dyskinesia in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2006, 29, 322-330.	0.7	31
113	The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. <i>Parkinsonism and Related Disorders</i> , 2020, 80, S54-S63.	2.2	31
114	Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa-Undertreated Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 174-181.	0.7	30
115	Long-Term Efficacy of Rasagiline in Early Parkinson's Disease. <i>International Journal of Neuroscience</i> , 2010, 120, 404-408.	1.6	29
116	Sertraline-induced exacerbation of Tics in Tourette's syndrome. <i>Movement Disorders</i> , 1995, 10, 682-684.	3.9	28
117	Deep Brain Stimulation of the Internal Segment of the Globus Pallidus in Delayed Runaway Dyskinesia. <i>Archives of Neurology</i> , 2006, 63, 1181.	4.5	28
118	Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. <i>Movement Disorders</i> , 2006, 21, 1998-2001.	3.9	28
119	Advances in the Pharmacologic Management of Early Parkinson Disease. <i>Neurologist</i> , 2007, 13, 126-132.	0.7	27
120	Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. <i>Journal of the Neurological Sciences</i> , 2017, 377, 137-143.	0.6	27
121	A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 783-789.	3.9	27
122	A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinson's Disease. <i>Sensors</i> , 2021, 21, 5437.	3.8	26
123	Substantial improvement in a Meige's syndrome patient with levetiracetam treatment. <i>Movement Disorders</i> , 2004, 19, 1518-1521.	3.9	25
124	Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2018-319918.	1.9	25
125	Bilateral human fetal striatal transplantation in Huntington's disease. <i>Neurology</i> , 2002, 58, 1704-1704.	1.1	24
126	Fentanyl-Induced Bradykinesia and Rigidity After Deep Brain Stimulation in a Patient With Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2009, 32, 48-50.	0.7	24



#	ARTICLE	IF	CITATIONS
127	Translocation breakpoint in two unrelated Tourette syndrome cases, within a region previously linked to the disorder. <i>Human Genetics</i> , 2003, 113, 154-161.	3.8	23
128	Pregabalin (Lyrica) in the treatment of essential tremor. <i>Movement Disorders</i> , 2007, 22, 139-141.	3.9	23
129	Caffeine, creatine, GRIN2A and Parkinson's disease progression. <i>Journal of the Neurological Sciences</i> , 2017, 375, 355-359.	0.6	23
130	Design of a cluster-randomized minority recruitment trial: RECRUIT. <i>Clinical Trials</i> , 2017, 14, 286-298.	1.6	23
131	Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. <i>CNS Spectrums</i> , 2022, 27, 208-217.	1.2	23
132	Clozapine withdrawal symptoms in a Parkinson's disease patient. <i>Movement Disorders</i> , 2002, 17, 1365-1367.	3.9	22
133	New considerations in the medical management of early Parkinson's disease: Impact of recent clinical trials on treatment strategy. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S17-S21.	2.2	22
134	Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. <i>Journal of Parkinson's Disease</i> , 2017, 7, 117-127.	2.8	22
135	Tardive dyskinesia: Out of the shadows. <i>Journal of the Neurological Sciences</i> , 2018, 389, 1-3.	0.6	22
136	Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials. <i>Annals of Pharmacotherapy</i> , 2018, 52, 1182-1194.	1.9	22
137	Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism: Relevance to neural transplantation. <i>World Neurosurgery</i> , 1996, 46, 384-388.	1.3	21
138	Use of nutritional supplements in Parkinson's disease patients. <i>Movement Disorders</i> , 2006, 21, 1098-1101.	3.9	21
139	Prevalence and treatment of non-motor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 545.	2.2	21
140	Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 250-266.	1.5	21
141	Levetiracetam for the treatment of generalized dystonia. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 469-471.	2.2	20
142	Transplantation of Human Fetal Striatal Tissue in Huntington's Disease: Rationale for Clinical Studies. <i>Novartis Foundation Symposium</i> , 2008, 231, 129-144.	1.1	20
143	An Update on Parkinson's Disease: Improving Patient Outcomes. <i>American Journal of Medicine</i> , 2014, 127, S3.	1.5	20
144	EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 543-558.	2.8	20

#	ARTICLE	IF	CITATIONS
145	IPX066: a novel carbidopa-levodopa extended-release formulation. Expert Review of Neurotherapeutics, 2012, 12, 133-140.	2.8	19
146	Levetiracetam-Induced Parkinsonism in a Huntington Disease Patient. Clinical Neuropharmacology, 2005, 28, 188-190.	0.7	18
147	Topiramate-induced Psychosis in Patients with Essential Tremor. Clinical Neuropharmacology, 2006, 29, 168-169.	0.7	18
148	Optimizing bioavailability in the treatment of Parkinson's disease. Neuropharmacology, 2007, 53, 791-800.	4.1	18
149	Targeting neurons in the gastrointestinal tract to treat Parkinson's disease. Clinical Parkinsonism & Related Disorders, 2019, 1, 2-7.	0.9	18
150	Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. Journal of Parkinson's Disease, 2021, 11, 1663-1675.	2.8	18
151	Chorea in a patient with cerebral palsy: Treatment with levetiracetam. Movement Disorders, 2005, 20, 762-764.	3.9	17
152	Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease. Frontiers in Neurology, 2021, 12, 645706.	2.4	17
153	Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America. Npj Parkinson's Disease, 2021, 7, 34.	5.3	17
154	Magnetic Resonance Imaging of Neurodegenerative Diseases. Journal of Neuroimaging, 1994, 4, 146-158.	2.0	16
155	Chorea as a side effect of gabapentin (Neurontin®) in a patient with complex regional pain syndrome Type 1. Clinical Rheumatology, 2008, 27, 389-390.	2.2	16
156	Higher neuron densities in the cerebral cortex and larger cerebellums may limit dive times of delphinids compared to deep-diving toothed whales. PLoS ONE, 2019, 14, e0226206.	2.5	16
157	Long-term, Open-label Study of Once-daily Ropinirole Prolonged Release in Early Parkinson's Disease. International Journal of Neuroscience, 2011, 121, 246-253.	1.6	15
158	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). Parkinsonism and Related Disorders, 2019, 62, 201-209.	2.2	15
159	Clinical trials aimed at detecting neuroprotection in Parkinson's disease. Neurology, 2006, 66, S58-68.	1.1	15
160	Sleep Attacks and Dopamine Agonists for Parkinson's Disease. CNS Drugs, 2003, 17, 593-600.	5.9	14
161	Carbidopa levodopa enteral suspension. Expert Opinion on Pharmacotherapy, 2015, 16, 2807-2817.	1.8	14
162	Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. American Journal of Cardiology, 2017, 119, 1111-1115.	1.6	14

#	ARTICLE	IF	CITATIONS
163	Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 839-845.	2.2	14
164	A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301). <i>Journal of Parkinson's Disease</i> , 2018, 8, 101-110.	2.2	14
165	On demand therapy for Parkinson's disease patients: Opportunities and choices. <i>Postgraduate Medicine</i> , 2021, 133, 721-727.	2.0	14
166	Tiagabine and exacerbation of essential tremor. <i>Movement Disorders</i> , 2007, 22, 2132-2133.	3.9	13
167	Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 627-634.	1.5	13
168	Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. <i>Journal of Parkinson's Disease</i> , 2019, 9, 591-600.	2.8	13
169	Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies. <i>Frontiers in Neurology</i> , 2020, 11, 576117.	2.4	13
170	Neurosurgery for Parkinson's Disease. <i>Seminars in Neurology</i> , 2001, 21, 091-102.	1.4	12
171	Role of the Pharmacist in the Effective Management of Wearing-Off in Parkinson's Disease. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1842-1849.	1.9	12
172	Treatment of Early Parkinson's Disease. <i>European Neurology</i> , 2009, 61, 206-215.	1.4	12
173	Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. <i>Movement Disorders</i> , 2010, 25, 927-931.	3.9	12
174	ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia. <i>JAMA Neurology</i> , 2017, 74, 1507.	9.0	12
175	Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. <i>Movement Disorders</i> , 2017, 32, 1335-1336.	3.9	12
176	A 500U/2mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. <i>International Journal of Neuroscience</i> , 2018, 128, 619-626.	1.6	12
177	The Narrowing Path for Nilotinib and Other Potential Disease-Modifying Therapies for Parkinson Disease. <i>JAMA Neurology</i> , 2020, 77, 295.	9.0	12
178	Article Commentary: Infectious Issues in Human Fetal Neural Transplantation. <i>Cell Transplantation</i> , 1997, 6, 553-556.	2.5	11
179	Treatment of Early Parkinson's Disease. <i>European Neurology</i> , 2009, 61, 193-205.	1.4	11
180	The UPDRS-8: A Brief Clinical Assessment Scale for Parkinson's Disease. <i>International Journal of Neuroscience</i> , 2012, 122, 333-337.	1.6	11

#	ARTICLE	IF	CITATIONS
181	Î±-Synuclein in Parkinson's disease: getting to the core of the matter. <i>Lancet Neurology</i> , The, 2015, 14, 785-786.	10.2	11
182	Botulinum toxin A for the treatment of cervical dystonia. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2017-2024.	1.8	10
183	Delayed Thalamic Intracranial Hemorrhage in an Essential Tremor Patient following Deep Brain Stimulation. <i>European Neurology</i> , 2008, 59, 187-189.	1.4	10
184	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 127-132.	2.2	10
185	Patterns and predictors of referrals to allied health services for individuals with Parkinson's disease: A Parkinson's foundation (PF) QII study. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 115-122.	2.2	10
186	Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 29.	5.3	10
187	MANAGEMENT OF EARLY PARKINSON'S DISEASE. <i>Medical Clinics of North America</i> , 1999, 83, 393-414.	2.5	9
188	Levetiracetam for the treatment of essential tremor. <i>Movement Disorders</i> , 2005, 20, 640-640.	3.9	9
189	Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia. <i>Neurology and Therapy</i> , 2021, 10, 307-320.	3.2	9
190	Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. <i>Movement Disorders</i> , 2021, 36, 2408-2412.	3.9	9
191	Letter to the editor. <i>Movement Disorders</i> , 1996, 11, 589-589.	3.9	8
192	Treatment of chorea with levetiracetam. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 87-87.	1.9	8
193	Use, maintenance and dose effects of cognitive speed of processing training in Parkinson's disease. <i>International Journal of Neuroscience</i> , 2017, 127, 841-848.	1.6	8
194	Communicating with participants during the conduct of multi-center clinical trials. <i>Clinical Trials</i> , 2016, 13, 592-596.	1.6	7
195	Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson's Disease and Dyskinesia. <i>Neurology and Therapy</i> , 2021, 10, 739-751.	3.2	7
196	Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 127-133.	2.2	6
197	Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 373, 116-123.	0.6	6
198	Valbenazine for the treatment of tardive dyskinesia. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1279-1287.	1.8	6

#	ARTICLE	IF	CITATIONS
199	Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study. <i>PLoS ONE</i> , 2021, 16, e0245827.	2.5	6
200	Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice. <i>Parkinson's Disease</i> , 2021, 2021, 1-10.	1.1	6
201	Depression in Patients with Parkinson's Disease. <i>CNS Drugs</i> , 2000, 13, 253-264.	5.9	5
202	P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease. <i>Advances in Therapy</i> , 2022, 39, 1881-1894.	2.9	5
203	Help cure Parkinson's disease: please don't waste the Golden Year. <i>Npj Parkinson's Disease</i> , 2018, 4, 29.	5.3	4
204	Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 141-145.	2.2	4
205	Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®). <i>Parkinsonism and Related Disorders</i> , 2021, 82, 133-137.	2.2	4
206	Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment. <i>Neurology and Therapy</i> , 2022, 11, 459-469.	3.2	4
207	Abbreviated MDS-LIPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search. <i>Parkinson's Disease</i> , 2022, 2022, 1-7.	1.1	4
208	Future therapies for Parkinson's disease. <i>Neurologic Clinics</i> , 2004, 22, S149-S166.	1.8	3
209	Vascular hemichorea/hemiballismus and topiramate. <i>Movement Disorders</i> , 2006, 21, 581-581.	3.9	3
210	Levetiracetam for Stiff-Person Syndrome. <i>Clinical Neuropharmacology</i> , 2008, 31, 301-302.	0.7	3
211	Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease. <i>Evidence-Based Medicine</i> , 2015, 20, 17-17.	0.6	3
212	Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 47-51.	2.2	3
213	Demonstration of a sensory trick in a case of writer's cramp. <i>Movement Disorders</i> , 2002, 17, 427-427.	3.9	2
214	45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study. <i>CNS Spectrums</i> , 2019, 24, 200-201.	1.2	2
215	Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey. <i>Parkinson's Disease</i> , 2021, 2021, 1-9.	1.1	2
216	Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapy. <i>Clinical Parkinsonism &amp; Related Disorders</i> , 2022, 6, 100123.	0.9	2

#	ARTICLE	IF	CITATIONS
217	Current treatment challenges and emerging therapies in Parkinson's disease. <i>Neurologic Clinics</i> , 2004, 22, ix-xi.	1.8	1
218	46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study. <i>CNS Spectrums</i> , 2019, 24, 201-201.	1.2	1
219	134 Long-Term Deutetrabenazine Treatment Is Associated with Sustained Treatment Response in Tardive Dyskinesia: Results from an Open-Label Extension Study. <i>CNS Spectrums</i> , 2020, 25, 284-285.	1.2	1
220	Carbidopa and Levodopa Extended Release Capsules (Rytary®) in Patients with and without Troublesome and Non-Troublesome Dyskinesia. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1-11.	2.8	1
221	Reply: Intravenous glutathione in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 962-963.	3.9	0
222	149 Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study. <i>CNS Spectrums</i> , 2018, 23, 92-93.	1.2	0
223	134 Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies. <i>CNS Spectrums</i> , 2018, 23, 84-84.	1.2	0
224	158 Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study. <i>CNS Spectrums</i> , 2018, 23, 97-97.	1.2	0
225	0617 Solriamfetol Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: Results from a Phase 2 Proof-of-Concept Trial. <i>Sleep</i> , 2019, 42, A245-A246.	1.1	0
226	34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities. <i>CNS Spectrums</i> , 2019, 24, 193-193.	1.2	0
227	35 Long-term Improvements in Site-Rated Outcomes with Deutetrabenazine Treatment in Patients with Tardive Dyskinesia. <i>CNS Spectrums</i> , 2019, 24, 193-194.	1.2	0
228	Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini. <i>Movement Disorders</i> , 2020, 35, 901-901.	3.9	0
229	AbobotulinumtoxinA: Evidence for long duration of response from 5 patient populations. <i>Toxicon</i> , 2021, 190, S21-S22.	1.6	0
230	IPX203 versus immediate release carbidopa-levodopa. , 0, , .		0